Condition: Sarcoma,Soft Tissue · Sponsor: University Hospital Heidelberg
The study is a randomized, open, prospective phase II study. The aim of the study is to evaluate the safety and feasibility of a hypofractionated, accelerated radiation approach based on the incidence of grade 3-5 NCI Common Terminology Criteria for Adverse Events (NCI-CTC-AE ) toxicity and / or termination of the planned therapy for any reason with neoadjuvant radiation with active beam guidance of the retroperitoneal Sarcomas using protons or carbon ions before a subsequent tumor resection.
This description comes directly from the study's public registry record.
Juergen Debus, Prof. · +496221 · juergen.debus@med.uni-heidelberg.de
Katharina Kozyra, Dr · +496221 · katharina.kozyra@med.uni-heidelberg.de
Always discuss trial participation with your own doctor first.
| University Hospital of Heidelberg, Radiation Oncology | Heidelberg, Germany | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04219202